comparemela.com

University Of Tuebingen Germany News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SkylineDx: Independent study shows favorable long term prognosis for CP-GEP Low Risk melanoma patients

ROTTERDAM, Netherlands and SAN DIEGO, March 17, 2023 /PRNewswire/ SkylineDx, an innovative diagnostics company, focused on research & development of molecular diagnostics for oncology and

United statesSan diegoDennis riedlPrnewswire skylinedxDharminder chahalFalcon rd programLaboratory developed testMerlin study initiativeUniversity of tuebingenUniversity of tuebingen germanyLow riskHigh riskEuropean journalSan diego california

Independent study shows favorable long term prognosis for CP-GEP Low Risk melanoma patients

/PRNewswire/ SkylineDx, an innovative diagnostics company, focused on research & development of molecular diagnostics for oncology and inflammatory.

United statesSan diegoPrnewswire skylinedxDharminder chahalFalcon rd programLaboratory developed testMerlin study initiativeUniversity of tuebingenUniversity of tuebingen germanyLow riskHigh riskEuropean journalSan diego california

Phoenix Molecular Designs Successfully Completes Patient Enrollment in Phase 1/1b Clinical Trial of PMD-026

SAN DIEGO and VANCOUVER, BC, Feb. 9, 2022 /PRNewswire/ - Phoenix Molecular Designs (PhoenixMD), a clinical stage biopharmaceutical company dedicat.

United statesSan diegoBritish columbiaSandrae dunnAndrew dorrCompany phaseNational cancer instituteGroup phoenix molecularKyushu universityMd anderson cancer centerUniversity of tuebingen germanyMolecular designsPhoenix molecular designsPhoenix molecularChief medical officerCancer center

Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

United statesKimberly steinmannJames dentzerFelix geisslerBristol myers squibbDora ferrariProgram managementZiopharm oncologyBoehringer ingelheimUniversity of tuebingen germanyCuris incUniversity of massachusettsEpix pharmaceuticalsLouis universityClinical developmentDrug administration

Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

United statesKimberly steinmannJames dentzerFelix geisslerBristol myers squibbDora ferrariProgram managementZiopharm oncologyBoehringer ingelheimUniversity of tuebingen germanyCuris incUniversity of massachusettsEpix pharmaceuticalsLouis universityClinical developmentDrug administration

vimarsana © 2020. All Rights Reserved.